Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Review

High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease

David S Pisetsky1,2 email, Helena Erlandsson-Harris3 email and Ulf Andersson4 email

1Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, USA

2Medical Research Service, Durham Veterans Administration Medical Center

3Department of Woman and Child Health, Pediatric Rheumatology Research Unit, Karolinska Institutet/Karolinska University Hospital L8:04, Stockholm S-171 76, Sweden

4Department of Medicine, Rheumatology Unit, Karolinska Institutet/Karolinska University Hospital Q2:09, Stockholm S-171 76, Sweden

author email corresponding author email

Arthritis Research & Therapy 2008, 10:209doi:10.1186/ar2440

Published: 30 June 2008

Abstract

High-mobility group box protein 1 (HMGB1) is a non-histone nuclear protein that has a dual function. Inside the cell, HMGB1 binds DNA, regulating transcription and determining chromosomal architecture. Outside the cell, HMGB1 can serve as an alarmin to activate the innate system and mediate a wide range of physiological and pathological responses. To function as an alarmin, HMGB1 translocates from the nucleus of the cell to the extra-cellular milieu, a process that can take place with cell activation as well as cell death. HMGB1 can interact with receptors that include RAGE (receptor for advanced glycation endproducts) as well as Toll-like receptor-2 (TLR-2) and TLR-4 and function in a synergistic fashion with other proinflammatory mediators to induce responses. As shown in studies on patients as well as animal models, HMGB1 can play an important role in the pathogenesis of rheumatic disease, including rheumatoid arthritis, systemic lupus erythematosus, and polymyositis among others. New approaches to therapy for these diseases may involve strategies to inhibit HMGB1 release from cells, its interaction with receptors, and downstream signaling.


© 1999-2008 BioMed Central Ltd unless otherwise stated < info@arthritis-research.com >   Terms and conditions